newsfilter
← Latest News
GlobeNewswire·

Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers

Company receives positive pre-IND feedback from US FDA for CLD-401, indicating agreement on its current development strategy as it advances towards a first-in-human study; targeting dosing first patient in Q1